Rat IL-10 Antibody

Detection of Recombinant Mouse and Rat IL‑10 by Western Blot. Western blot shows 25 ng of Recombinant Rat IL-10 (Catalog # 522-RLB), Recombinant Human IL-10 (Catalog # 217-IL) and Recombinant Mouse IL-10 (Catalog # 417-ML). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Rat IL-10 Monoclonal Antibody (Catalog # MAB519) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for IL-10 at approximately 15 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3.

Detection of Rat IL-10 by Immunohistochemistry Nrg-1 promotes Treg cell response in the injured spinal cord. a, b Representative images of the gating strategy for flow cytometry after singlet selection are provided for vehicle- and Nrg-1-treated groups. c At 3-day post-injury, the number of CD3+CD4+ T cells in the spinal cord was significantly higher in vehicle-treated animals compared to uninjured control group. There was no significant difference in the population of infiltrated helper T cells and the number of FoxP3+ Treg cells (CD3+CD4+FoxP3+) between vehicle- and Nrg-1-treated groups. However, the population of IL-10 producing CD4+ T cells (CD3+CD4+IL-10+) was significantly increased in Nrg-1-treated animals in comparison to vehicle-treated group. d At 7 days post-SCI, despite no significant difference in the total helper and regulatory T cell populations between vehicle- and Nrg-1-treated groups, a significant reduction (1.9-fold) was observed in IFN gamma producing effector T cell population in Nrg-1-treated SCI rats compared to their vehicle-treated counterparts. e At 14 days post-SCI, infiltrated helper T cells reached their lowest level among all examined time-points, and Nrg-1 treatment had no significant effect on the total helper T cell population. IL-10 expressing Treg cells were significantly higher in both vehicle and Nrg-1 injured rats compared to uninjured animals. Nrg-1-treated animals showed a significantly higher number of Treg cells in their spinal cord at 14-day time-point compared to vehicle-treated rats. f However, at chronic (42-day) time-point, the number of T helper cells reached a maximum, with Nrg-1-treated animals harboring a significantly decreased population of CD4+ T-cells in their spinal cord compared to the vehicle-treated group. Most importantly, CD3+CD4+FoxP3+ and CD3+CD4+IL-10+ regulatory T cell populations were significantly increased in Nrg-1-treated groups. g Immunohistochemical images show the presence of Treg cells in the perilesional area (N = 5/group/time-point, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA followed by Holm-Sidak post hoc test) Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1093-9), licensed under a CC-BY license. Not internally tested by R&D Systems.

Detection of Rat IL-10 by Immunohistochemistry Nrg-1 treatment promotes Breg cell population following SCI. a Representative images of the gating strategy for flow cytometry of spinal cord are provided. b At 7 days post-injury, the number of CD45RA+ B cells was significantly increased in the spinal cord without any significant difference in the total and regulatory B cell populations between vehicle- and Nrg-1-treated groups. c At 14-day post-SCI, a significant increase in the number of Breg cells was observed in Nrg-1-treated animals compared to vehicle-treated group. d Chronically at 42 days post-SCI, the number of B cells in the spinal cord reached the highest level compared to all earlier time-points. Nrg-1 treatment resulted in a significant increase in the number of infiltrated B cells in the spinal cord and promoted IL-10 expressing Breg cells compared to vehicle treatment. e Immunohistochemical analysis verified the presence of Breg cells in the perilesional area of the injured spinal cord. f Representative images of the gating strategy for flow cytometry of blood are provided. g Analysis of the blood revealed a significant decline in B cell population at 7 days post-SCI without any significant change in the Breg cell population at this time-point. h, i No significant change in total and regulatory B cell populations were observed in the blood at 14- and 42-day time-points. (N = 5/group/time-point, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA followed by Holm-Sidak post hoc test) Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-018-1093-9), licensed under a CC-BY license. Not internally tested by R&D Systems.